Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

VVOSBullishEarningsShort Term

High materiality7/10

Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

StockNews.AIAug 14, 4:28 PM EDT1 source

Trading thesisImportance 7/10

Bullish near-term; continued revenue growth and partnerships could push VVOS higher over 3–9 months.

AI summary

What happened and why it matters

Vivos Therapeutics posted Q2 2026 revenue of $5.2 million, up 35% YoY, with six-month revenue of $10.3 million (up 51%). Gross margin rose to 57% in Q2 and 58% YTD as higher volumes improve mix, while operating expenses grew 12%. Management cites capacity expansion, an AI software conversion at SCN, and stronger referrals as catalysts, with potential multi-market cardiology partnerships wrapping up in Florida and Arizona, supporting a near-term revenue trajectory despite ongoing cash burn.

Q2 revenue growth confirms improving top-line trajectory.
Gross margin expansion supports better unit economics.
Liquidity risk remains with $1.8M cash; equity deficit $3.8M.
Strategic partnerships with large cardiology groups could unlock larger TAM.

Sentiment rationale

Positive top-line momentum (35% Q2 growth; 51% six-month), margin improvements (57% Q2, 58% H1) and operating leverage amid capacity expansion provide a constructive view on profitability trajectory. Progress on partnerships and AI-enabled initiatives could unlock incremental revenue. However, near-term liquidity risk (cash $1.8M; equity deficit $3.8M) and ongoing losses cap upside until financing or cost controls improve cash burn.

Key facts

01
Revenue $5.2M in Q2'26; six months $10.3M, up 35%/51% YoY.
02
Gross margin 57% Q2; 58% H1; operating expenses up 12%.
03
Capacity expansion, SCN AI conversion, and referrals drive demand gains.
04
Cash $1.8M; stockholders’ equity deficit $3.8M; six-month net loss $13.27M.
05
Pending cardiology partnerships in Florida/Arizona; Q3 gains already visible.

Earnings

Category: Earnings. The release summarizes quarterly results and strategic actions, framing VVOS’s near-term revenue trajectory and cash-burn dynamics around capacity expansion, SCN AI conversion, and upcoming partnerships.